Retention, Urinary
0
Pipeline Programs
1
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
ColoplastAustralia - Mulgrave
4 programsSpeediCath® Standard femaleN/A1 trial
SpeediCath® Standard maleN/A1 trial
SpeediCath® Standard male new coatingN/A1 trial
SpeediCath® Standard male or femaleN/A1 trial
Active Trials
+1 more trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
ColoplastSpeediCath® Standard male new coating
ColoplastSpeediCath® Standard female
ColoplastSpeediCath® Standard male
ColoplastSpeediCath® Standard male or female
Clinical Trials (4)
Total enrollment: 93 patients across 4 trials
New Coating for Urinary Intermittent Catheters
Start: May 2025Est. completion: Jun 202532 patients
N/ACompleted
Investigation of Non-CE Marked Intermittent Catheters for Females
Start: Dec 2020Est. completion: May 202115 patients
N/ACompleted
Investigation of Non-CE Marked Intermittent Catheters.
Start: Oct 2020Est. completion: Jan 202116 patients
N/ACompleted
Investigation of New Intermittent Catheters in Healthy Volunteers
Start: Mar 2020Est. completion: Sep 202030 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.